A CDC panel declined to vote on whether to resume US use of Johnson & Johnson’s Covid-19 vaccine, effectively putting the jabs on ice until more data is available on rare cases of blood clotting linked to the product.

Members of the CDC advisory committee on Wednesday said they want more information about the types of people, by such factors as age and gender, who may be at most risk of blood clots after taking the Johnson & Johnson vaccine.

It’s not clear when a recommendation will be made, but the panel reportedly may re-convene in as soon as seven to 10 days. Its next regular meeting is scheduled for May 5, 2021.

It’s also unclear what more Johnson & Johnson can tell the committee members that hasn’t already been reported.

The FDA and CDC on Tuesday recommended that states temporarily halt use of the vaccine, citing reports that six people experienced cerebral venous sinus thrombosis (CVST) blood clots after receiving their shots.

One of those six died and another is in critical condition, but the clots appear to be extremely rare. As for risks by category, the FDA and CDC said all six clotting cases involved women between the ages of 18 and 48.

The decision to delay action means the Johnson & Johnson vaccine will remain sidelined indefinitely while Pfizer-BioNTech and Moderna inoculations will continue to be administered across the USA.

Johnson & Johnson’s Covid-19 vaccine got FDA emergency use authorization in late February, more than two months after the Pfizer-BioNTech and Moderna rollouts began.

But it’s considered a key part of the US Covid-19 vaccine arsenal, especially in remote areas, at least partly because it requires only one dose for full inoculation.

However, there are more than enough Pfizer-BioNTech and Moderna jabs in distribution to maintain the current pace of vaccinations and meet President Joe Biden’s goal of having 200 million doses administered by the end of April, 2021.

But the US pause is delaying the rollout of Johnson & Johnson jabs in Europe, and with Biden focusing on making vaccines available to all Americans before sharing them with other countries, the suspension will affect the global pace of inoculations.

RT. com / ABC Flash Point News 2021.

4.8 5 votes
Article Rating
Subscribe
Notify of
guest
6 Comments
Inline Feedbacks
View all comments
Rockefeller
Rockefeller
Guest
Reply to  Sandokan
15-04-21 01:18

There have been more adverse reactions from Pfizer and Moderna, maybe that’s why they pulled it. It doesn’t have enough adverse reactions to meet the quota.

Sinalco
Sinalco
Guest
15-04-21 01:19

More untested goods, what could possibly go wrong…

Yakutsk
Yakutsk
Guest
15-04-21 01:20

There have been more adverse reactions from Pfizer and Moderna, maybe that’s why they pulled it out. It doesn’t have enough adverse reactions to meet the quota?